Full Press Release Details
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Focus remains on cost control to maximize the value of our royalty assets
Company announces evaluation of strategic alternatives
BOCA RATON, Fla. November 14, 2023 TherapeuticsMD, Inc. ( TherapeuticsMD or the Company )
(NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.
As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty
assets, stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD.
Third Quarter 2023 Financial Results
Net Loss from Continuing Operations
License and Service Revenues from Continuing Operations
Total Operating Expenses from Continuing Operations
Company Announces Evaluation of Strategic Alternatives
About TherapeuticsMD
TherapeuticsMD was previously a women s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of
women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and
development or commercial operations.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements
relating to TherapeuticsMD s objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets,
licensing, or other strategic transactions, and the completion of such a review process as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are often characterized by terminology such as believes, hopes, may, anticipates, should, intends,
plans, will, expects, estimates, projects, positioned, strategy and similar expressions and are based on assumptions and assessments made in light of
management s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press
release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled
Risk Factors in the company s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether Mayne Pharma will be successful at commercializing the products that it licensed and acquired from
TherapeuticsMD; whether the company is successful in winding down its operations and the costs associated therewith, including the company s ability to obtain any additional financing necessary therefor and any adjustments to the net working
capital purchased as part of the Mayne Pharma transaction; whether the company is successful in identifying strategic pathways to create additional shareholder value; the company s ability to remain listed on Nasdaq; the impact of product
liability lawsuits; the impact of leadership transitions; and the volatility of the trading price of the company s common stock.
| Marlan D. Walker | Lisa M. Wilson | |
| Chief Executive Officer 561-961-1900 IR@TherapeuticsMD.com | In-Site Communications, Inc. 212-452-2793 lwilson@insitecony.com |